Clinical Context
Type 2 diabetes is paradoxically associated with increased fracture risk despite often-normal or even elevated bone mineral density (BMD). This “diabetes bone paradox” reflects impaired bone quality—changes in microarchitecture, collagen cross-linking, and accumulated advanced glycation end-products (AGEs) that weaken bone independent of BMD. Postmenopausal women with diabetes face compounded risk from both estrogen deficiency and diabetes-related bone fragility.
The choice of diabetes medication may influence bone health. Thiazolidinediones (pioglitazone, rosiglitazone) increase fracture risk, particularly in women, through PPAR-gamma activation that shifts bone marrow stromal cells toward adipocyte rather than osteoblast differentiation. SGLT2 inhibitors have raised concerns about potential bone effects, though evidence remains mixed. In contrast, metformin appears bone-neutral or possibly protective.
DPP-4 inhibitors like sitagliptin have theoretical reasons for bone benefit. GLP-1, which DPP-4 inhibitors increase by preventing its degradation, has receptors on osteoblasts and may promote bone formation. GIP (also preserved by DPP-4 inhibition) directly stimulates osteoblast activity and inhibits osteoclast function. This trial specifically tested whether sitagliptin could protect bone in women with type 2 diabetes—a population at heightened skeletal risk.
Study Summary (PICO Framework)
Summary:
In women with type 2 diabetes, sitagliptin treatment at standard dosing significantly preserved total hip bone mineral density (T score) compared to placebo, with no consistent effects at other skeletal sites or on bone turnover markers.
| PICO | Description |
|---|---|
| Population | Women with type 2 diabetes mellitus. |
| Intervention | Sitagliptin at standard therapeutic dosing (likely 100 mg daily) over the study period. |
| Comparison | Placebo treatment under identical conditions. |
| Outcome | Sitagliptin preserved total hip T score vs placebo. No significant changes at lumbar spine or other sites. Bone turnover markers showed no consistent pattern. |
Clinical Pearls
1. Hip BMD is the clinically relevant site. While the lack of effect at other sites (presumably lumbar spine, femoral neck) might seem inconsistent, hip fractures are the most devastating osteoporotic fractures—associated with 20-30% one-year mortality and significant permanent disability. Preserving hip BMD specifically addresses the highest-stakes skeletal complication. The hip is also predominantly cortical bone, which may respond differently to incretin effects than the more trabecular lumbar spine.
2. The mechanism may be independent of bone turnover markers. The absence of consistent changes in bone turnover markers (like P1NP, CTX) despite BMD preservation is intriguing. This could suggest that sitagliptin works through bone quality improvements rather than gross remodeling changes, through local rather than systemic effects, or that standard markers don’t capture the relevant biology. Alternatively, the sample size may have been insufficient to detect marker changes.
3. This represents a potential advantage over some alternative therapies. For women with diabetes and osteoporosis risk, medication choice matters. Thiazolidinediones increase fracture risk and should generally be avoided. SGLT2 inhibitors have uncertain skeletal effects. GLP-1 agonists appear bone-neutral in most studies. If sitagliptin actively protects bone, this could favor DPP-4 inhibitor selection in women with skeletal concerns—though glycemic efficacy and cardiovascular benefits must also be weighed.
4. Incretin-based bone protection has biological plausibility. GIP receptors are present on osteoblasts and osteoclasts. GIP directly stimulates osteoblast activity and suppresses osteoclast-mediated bone resorption. GLP-1 also has skeletal effects, though its receptor distribution on bone cells is less well characterized. By preventing degradation of both GIP and GLP-1, DPP-4 inhibitors provide dual incretin enhancement that could translate to bone benefits—even if the specific mechanism remains unclear.
Practical Application
Consider sitagliptin (or DPP-4 inhibitors generally) for women with diabetes at skeletal risk. When intensifying diabetes therapy in postmenopausal women, particularly those with osteopenia, osteoporosis, prior fracture, or other fracture risk factors, the SLowDOWN trial provides modest support for considering a DPP-4 inhibitor. While sitagliptin shouldn’t be chosen solely for bone protection, it represents a potential added benefit in the right patient.
Don’t use sitagliptin as osteoporosis treatment. The bone effects are modest (preservation, not improvement) and limited to one site. Women with established osteoporosis need proven anti-resorptive or anabolic therapies (bisphosphonates, denosumab, teriparatide, romosozumab). Sitagliptin is a diabetes medication with possible skeletal benefits—not a bone drug with glucose-lowering properties.
Balance against other considerations. Sitagliptin is glycemically modest compared to GLP-1 agonists, SGLT2 inhibitors, and insulin. It lacks the cardiovascular and renal benefits of SGLT2 inhibitors (for those with heart failure or CKD) and GLP-1 agonists (for ASCVD). The bone benefit identified here is one factor among many in medication selection. For a patient with ASCVD or heart failure, cardioprotective agents take priority over theoretical bone benefits.
Ensure comprehensive osteoporosis management. Regardless of diabetes medication choice, women with diabetes need bone health assessment. Consider DEXA screening per osteoporosis guidelines, calcium and vitamin D adequacy, fall risk assessment, and appropriate osteoporosis treatment when indicated. Diabetes medication choice is secondary to these fundamental interventions.
How This Study Fits Into the Broader Evidence
The SLowDOWN trial adds to limited data on DPP-4 inhibitors and bone. Previous observational studies suggested possible fracture risk reduction with DPP-4 inhibitors compared to other diabetes medications, but confounding in these analyses is substantial. The large cardiovascular outcome trials (TECOS, SAVOR-TIMI 53, CARMELINA) were not designed for skeletal endpoints, and fracture data from these trials has been inconclusive.
GLP-1 receptor agonists, which work through a related but distinct mechanism, have generally shown bone-neutral effects in trials. The SUSTAIN 6 and PIONEER 6 trials with semaglutide, for example, showed no excess fracture risk. The difference between DPP-4 inhibitors (which preserve both GIP and GLP-1) and GLP-1 agonists (which activate only GLP-1 receptors) might be relevant—GIP’s direct bone effects may be the key mediator.
Current endocrine society guidelines don’t make specific recommendations about diabetes medication choice based on skeletal effects, except to avoid thiazolidinediones in patients at fracture risk. This study contributes to the evidence base that may eventually inform such guidance.
Limitations to Consider
The study population and sample size aren’t detailed in the available summary. BMD is a surrogate endpoint; fracture outcomes would be more definitive but require larger, longer trials. The selective effect at the hip without consistent changes elsewhere raises questions about mechanism and reproducibility. Results may not generalize to men or to other DPP-4 inhibitors. The trial name (SLowDOWN) suggests investigators expected bone-slowing effects, potentially introducing investigator bias.
Bottom Line
The SLowDOWN trial found that sitagliptin preserved total hip bone mineral density in women with type 2 diabetes compared to placebo, though effects at other skeletal sites were inconsistent. For postmenopausal women with diabetes and skeletal risk factors, DPP-4 inhibitors may offer a modest bone-preserving advantage over some alternatives—particularly thiazolidinediones, which should be avoided. This represents one factor among many in diabetes medication selection; glycemic efficacy and cardiorenal benefits remain primary considerations for most patients.
Source: Barchetta, Ilaria, et al. “Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial.” Read article here.
